Adcock Ingram is a leading South African pharmaceutical manufacturer, marketer and distributor. The company occupies 10% share of the private pharmaceutical market in South Africa with a strong presence in over-the-counter (OTC) brands. Adcock is als... More
DISHMAN PHARMA ADCOCK INGRAM |
EQUITY SHARE DATA | |||||
---|---|---|---|---|---|
DISHMAN PHARMA Mar-16 |
ADCOCK INGRAM Jun-14 |
DISHMAN PHARMA/ ADCOCK INGRAM |
5-Yr Chart Click to enlarge
|
||
High | Rs | 374 | 314 | - | |
Low | Rs | 129 | 226 | - | |
Sales per share (Unadj.) | Rs | 197.0 | 93.4 | - | |
Earnings per share (Unadj.) | Rs | 21.2 | -23.5 | - | |
Cash flow per share (Unadj.) | Rs | 34.7 | -19.5 | - | |
Dividends per share (Unadj.) | Rs | 2.00 | 0 | - | |
Avg Dividend yield | % | 0.8 | 0 | - | |
Book value per share (Unadj.) | Rs | 179.9 | 73.3 | - | |
Shares outstanding (eoy) | m | 80.70 | 168.78 | - | |
Bonus / Rights / Conversions | 0 | 0 | - | ||
Price / Sales ratio | x | 1.3 | 2.9 | 44.1% | |
Avg P/E ratio | x | 11.9 | -11.5 | -103.4% | |
P/CF ratio (eoy) | x | 7.3 | -13.9 | -52.3% | |
Price / Book Value ratio | x | 1.4 | 3.7 | 38.0% | |
Dividend payout | % | 9.4 | 0 | - | |
Avg Mkt Cap | Rs m | 20,307 | 45,603 | 44.5% | |
No. of employees | `000 | NA | 4.3 | 0.0% | |
Total wages/salary | Rs m | 5,355 | 2,862 | 187.1% | |
Avg. sales/employee | Rs Th | 0 | 3,671.4 | - | |
Avg. wages/employee | Rs Th | 0 | 666.7 | - | |
Avg. net profit/employee | Rs Th | 0 | -925.1 | - |
INCOME DATA | |||||
---|---|---|---|---|---|
Net Sales | Rs m | 15,898 | 15,761 | 100.9% | |
Other income | Rs m | 265 | 110 | 240.5% | |
Total revenues | Rs m | 16,163 | 15,872 | 101.8% | |
Gross profit | Rs m | 4,103 | -2,731 | -150.2% | |
Depreciation | Rs m | 1,091 | 680 | 160.3% | |
Interest | Rs m | 944 | 427 | 221.2% | |
Profit before tax | Rs m | 2,334 | -3,728 | -62.6% | |
Minority Interest | Rs m | 0 | -10 | -0.0% | |
Prior Period Items | Rs m | 0 | 0 | - | |
Extraordinary Inc (Exp) | Rs m | 0 | 0 | - | |
Tax | Rs m | 624 | 233 | 267.7% | |
Profit after tax | Rs m | 1,710 | -3,971 | -43.1% | |
Gross profit margin | % | 25.8 | -17.3 | -148.9% | |
Effective tax rate | % | 26.7 | -6.2 | -427.7% | |
Net profit margin | % | 10.8 | -25.2 | -42.7% |
BALANCE SHEET DATA | |||||
---|---|---|---|---|---|
Current assets | Rs m | 11,018 | 11,544 | 95.4% | |
Current liabilities | Rs m | 9,517 | 6,495 | 146.5% | |
Net working cap to sales | % | 9.4 | 32.0 | 29.5% | |
Current ratio | x | 1.2 | 1.8 | 65.1% | |
Inventory Days | Days | 57 | 111 | 51.4% | |
Debtors Days | Days | 3 | 124 | 2.8% | |
Net fixed assets | Rs m | 18,787 | 6,729 | 279.2% | |
Share capital | Rs m | 161 | 73 | 220.6% | |
Net worth | Rs m | 14,516 | 12,371 | 117.3% | |
Long term debt | Rs m | 4,189 | 4,347 | 96.4% | |
Total assets | Rs m | 29,805 | 23,369 | 127.5% | |
Interest coverage | x | 3.5 | -7.7 | -44.9% | |
Debt to equity ratio | x | 0.3 | 0.4 | 82.1% | |
Sales to assets ratio | x | 0.5 | 0.7 | 79.1% | |
Return on assets | % | 8.9 | -15.2 | -58.7% | |
Return on equity | % | 11.8 | -32.1 | -36.7% | |
Return on capital | % | 17.5 | -19.8 | -88.5% |
CASH FLOW | |||||
---|---|---|---|---|---|
From Operations | Rs m | 2,786 | 1,345 | 207.1% | |
From Investments | Rs m | -1,529 | -413 | 370.1% | |
From Financial Activity | Rs m | -941 | 3,945 | -23.8% | |
Net Cashflow | Rs m | 317 | 4,878 | 6.5% |
Compare DISHMAN PHARMA With: ACTAVIS (US) MYLAN (US) TEVA PHARMA (Israel)
Compare DISHMAN PHARMA With: AUROBINDO PHARMA VIMTA LABS SYNCOM FORMULATIONS ADESHWAR MEDITEX CIPLA
After opening the day on high, Indian share markets reversed the trend as the session progressed and ended the lower.